An interventional study of Kava and Kratom Herbal Supplement and Kava Herbal Supplement in Herb-Herb Interaction and Pharmacokinetics, sponsored by Botanic Tonics, LLC. Active, not recruiting at 1 site in Canada. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Botanic Tonics, LLC · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being conducted to evaluate how different formulations of the Feel Free® Tonic containing Kava, Kratom, or a combination of both are processed in the body in healthy adults. The goal is to compare the pharmacokinetic profiles and safety of the combined herbal formulation with Kava alone and Kratom alone to better understand how these ingredients behave when taken individually versus together.
This is a randomized, double blind, 3 period crossover pharmacokinetic study in healthy adults designed to compare the pharmacokinetic profiles of a combined Kava and Kratom formulation with Kava alone and Kratom alone under fasted conditions. The primary objective is to evaluate systemic exposure and key pharmacokinetic parameters following each treatment. Secondary objectives include the assessment of safety and tolerability across all study products. The investigational products are oral liquid herbal supplements containing Kava, Kratom, or a combination of both. The study will also explore subjective effects, well-being, mood, and participant perceptions of the study products. Each participant will receive all three treatments in a randomized sequence with washout periods between dosing, allowing within subject comparison of pharmacokinetic outcomes.
Botanic Tonics, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals with must agree to comply with the following requirements:
Exclusion Criteria:
Currently consumes more than two (2) standard alcoholic beverages per day on average for 4 weeks.
Note: A standard alcoholic beverage is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of liquor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Product of 380 mg Kava root extract and 1480 mg of dried Kratom Leaf powder per bottle
Dietary Supplement: Kava and Kratom Herbal Supplement
Active Product of 380 mg Kava root extract per bottle
Dietary Supplement: Kava Herbal Supplement
Active Product of 1480 mg dried Kratom Leaf powder per bottle
Dietary Supplement: Kratom Herbal Supplement
Half- Strength Feel Free Classic Tonic (TP1)
Kava Only Variant - Feel Free Tonic (TP2)
Kratom Only Variant - Feel Free Tonic (TP3)
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) for Kavain
AUC0-24 for kavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) for Dihydrokavain
AUC0-24 for dihydrokavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) for Mitragynine
AUC0-24 for mitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) for 7-Hydroxymitragynine
AUC0-24 for 7-Hydroxymitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours (AUC0-72) for Kavain
AUC0-72 for kavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) for Kavain
Peak plasma concentration of kavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 of each treatment period (0-12 hours post-dose)
Time to Maximum Plasma Concentration (Tmax) for Kavain
Time to reach maximum observed plasma concentration of kavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Terminal Elimination Half-Life (T½) for Kavain
Terminal elimination half-life of kavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours (AUC0-72) for Dihydrokavain
AUC0-72 for dihydrokavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) for Dihydrokavain
Peak plasma concentration of dihydrokavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 of each treatment period (0-12 hours post-dose)
Time to Maximum Plasma Concentration (Tmax) for Dihydrokavain
Time to reach maximum observed plasma concentration of dihydrokavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Terminal Elimination Half-Life (T½) for Dihydrokavain
Terminal elimination half-life of dihydrokavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours (AUC0-72) for Mitragynine
AUC0-72 for mitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) for Mitragynine
Peak plasma concentration of mitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 of each treatment period (0-12 hours post-dose)
Time to Maximum Plasma Concentration (Tmax) for Mitragynine
Time to reach maximum observed plasma concentration of mitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Terminal Elimination Half-Life (T½) for Mitragynine
Terminal elimination half-life of mitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours (AUC0-72) for 7-Hydroxymitragynine
AUC0-72 for 7-Hydroxymitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) for 7-Hydroxymitragynine
Peak plasma concentration of 7-Hydroxymitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 of each treatment period (0-12 hours post-dose)
Time to Maximum Plasma Concentration (Tmax) for 7-Hydroxymitragynine
Time to reach maximum observed plasma concentration of 7-Hydroxymitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 and Day 2 of each treatment period (0-24 hours post-dose)
Terminal Elimination Half-Life (T½) for 7-Hydroxymitragynine
Terminal elimination half-life of 7-Hydroxymitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for Kavain
AUC0-∞ for kavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Ratio of area under the plasma concentration from 0 to 24 Hours (AUC0-24) to area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for Kavain
Ratio of exposure from 0-24 hours relative to total exposure for kavain.
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for Dihydrokavain
AUC0-∞ for Dihydrokavain following single-dose administration of Kava alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Ratio of area under the plasma concentration from 0 to 24 Hours (AUC0-24) to area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for Dihydrokavain
Ratio of exposure from 0-24 hours relative to total exposure for Dihydrokavain.
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for Mitragynine.
AUC0-∞ for mitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Ratio of area under the plasma concentration from 0 to 24 Hours (AUC0-24) to area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for Mitragynine
Ratio of exposure from 0-24 hours relative to total exposure for mitragynine.
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for 7-Hydroxymitragynine.
AUC0-∞ for 7-Hydroxymitragynine following single-dose administration of Kratom alone or combined Kava and Kratom
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Ratio of area under the plasma concentration from 0 to 24 Hours (AUC0-24) to area under the plasma concentration time curve extrapolated to infinity (AUC0-∞) for 7-Hydroxymitragynine
Ratio of exposure from 0-24 hours relative to total exposure for 7-Hydroxymitragynine.
Time frame: Day 1 to Day 4 of each treatment period (0-72 hours post-dose)
Area under the curve at steady state from 0 to 12 hours (AUC0-12,ss) for Kavain
AUC0-12,ss for Kavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Maximum Observed Plasma Concentration at steady state (Cmax,ss) for Kavain
Cmax,ss for kavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Time to Maximum Plasma Concentration at Steady State (Tmax,ss) for Kavain
Tmax,ss of kavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Terminal Elimination Half-Life at Steady State (T½,ss) for Kavain
T½,ss for kavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞) for Kavain
AUC0-∞,ss for kavain following multiple-day dosing administration of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Ratio of area under the plasma concentration at steady state from 0 to 12 Hours (AUC0-12,ss) to area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞,ss) for Kavain
Ratio of exposure from 0-12 hours relative to total exposure at steady state for kavain.
Time frame: Day 14 of each treatment period
Area under the curve at steady state from 0 to 12 hours (AUC0-12,ss) for Dihydrokavain
AUC0-12,ss for dihydrokavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Maximum Observed Plasma Concentration at steady state (Cmax,ss) for Dihydrokavain
Cmax,ss for dyhydrokavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Time to Maximum Plasma Concentration at Steady State (Tmax,ss) for Dihydrokavain
Tmax,ss of dihydrokavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Terminal Elimination Half-Life at Steady State (T½,ss) for Dihydrokavain
T½,ss for dihydrokavain following a multiple-day dosing of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞) for Dihydrokavain
AUC0-∞,ss for dihydrokavain following multiple-day dosing administration of Kava alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Ratio of area under the plasma concentration at steady state from 0 to 12 Hours (AUC0-12,ss) to area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞,ss) for Dihydrokavain
Ratio of exposure from 0-12 hours relative to total exposure at steady state for dihydrokavain.
Time frame: Day 14 of each treatment period
Area under the curve at steady state from 0 to 12 hours (AUC0-12,ss) for Mitragynine
AUC0-12,ss for mitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Maximum Observed Plasma Concentration at steady state (Cmax,ss) for Mitragynine
Cmax,ss for mitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Time to Maximum Plasma Concentration at Steady State (Tmax,ss) for Mitragynine
Tmax,ss for mitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Terminal Elimination Half-Life at Steady State (T½,ss) for Mitragynine
T½,ss for mitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞) for Mitragynine
AUC0-∞,ss for mitragynine following multiple-day dosing administration of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Ratio of area under the plasma concentration at steady state from 0 to 12 Hours (AUC0-12,ss) to area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞,ss) for Mitragynine
Ratio of exposure from 0-12 hours relative to total exposure at steady state for mitragynine.
Time frame: Day 14 of each treatment period
Area under the curve at steady state from 0 to 12 hours (AUC0-12,ss) for 7-Hydroxymitragynine
AUC0-12,ss for 7-Hydroxymitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Maximum Observed Plasma Concentration at steady state (Cmax,ss) for 7-Hydroxymitragynine
Cmax,ss for 7-Hydroxymitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Time to Maximum Plasma Concentration at Steady State (Tmax,ss) for 7-Hydroxymitragynine
Tmax,ss for 7-Hydroxymitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Terminal Elimination Half-Life at Steady State (T½,ss) for 7-Hydroxymitragynine
T½,ss for 7-Hydroxymitragynine following a multiple-day dosing of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞) for 7-Hydroxymitragynine
AUC0-∞,ss for 7-Hydroxymitragynine following multiple-day dosing administration of Kratom alone or combined Kava and Kratom
Time frame: Day 14 of each treatment period
Ratio of area under the plasma concentration at steady state from 0 to 12 Hours (AUC0-12,ss) to area under the plasma concentration time curve extrapolated to infinity at steady state (AUC0-∞,ss) for 7-Hydroxymitragynine
Ratio of exposure from 0-12 hours relative to total exposure at steady state for 7-Hydroxymitragynine.
Time frame: Day 14 of each treatment period
Modified Drug Effects Questionnaire (DEQ)
To assess the effect of TP on subjective drug effects compared to comparator. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses the participants subjective experience after consuming the TP.
Time frame: Days 1 and 14 of each treatment period
Overall Well Being, Health, and Pain
To assess the effect of TP on overall well-being, health, and pain compared to comparator. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses overall quality of life with questions specifically on physical health and pain. Higher scores indicate better overall well-being, health, and pain.
Time frame: Pre-dose Day 1 to Pre-dose Days 7 and 14 of each treatment period
Ecological Momentary Assessment (EMA) Survey
To assess the effect of TP on mood compared to comparator. A non-validated questionnaire consisting of 13 questions assessing the participants emotional and mental/physical states they are feeling "right now." This questionnaire uses bipolar visual analogue scales in which participants how they feel "right now" on lines between two opposite feelings or physical sensations.
Time frame: Days 2, 4, 6, 8, 10, 12, and 14 of each treatment period
Study Product Perception & Attitude Survey
To assess the effect of TP on study product perceptions and attitudes compared to comparator. A non-validated questionnaire consisting of multiple items assessing participants' subjective experiences with the study product, including effects on daily functioning, energy, sleep, mood, mild stress/anxiety, focus, mild pain, muscle recovery, tolerability, and product quality. Items are scored on a 5#point Likert scale ranging from "Strongly Disagree" to "Strongly Agree." Higher scores indicate more favorable perceptions of the study product (except for the side effects item, where higher scores indicate greater perceived side effects).
Time frame: Days 7 and 14 of each treatment period
Appraisal of Effects Survey
To assess participant-reported perceptions of the effects of the study product compared to comparator. A non-validated, self-administered questionnaire consisting of multiple items assessing participants' subjective experiences with the study product, including overall effect on how they feel, liking of the product, pain, muscle fatigue, mental focus/concentration, and calmness/stress. Items are scored using a 100-point visual analogue scale ranging from "Not at all" (0) to "Extremely" (100). Higher scores indicate greater perceived effects of the study product.
Time frame: Days 2, 4, 6, 8, 10, 12, and 14
Safety Assessments - Incidence of Treatment-Emergent Adverse Events
Number and percentage of participants experiencing treatment-emergent adverse events from first dose through follow-up.
Time frame: From first dose through follow-up visit
Safety Assessment: Change in Subjective Opiate Withdrawal Scale (SOWS)
To test the safety of TP by assessing the change in SOWS. This validated questionnaire is used to assess participants intensity of potential opioid withdrawal symptoms. Items are scored on a 5-point Likert scale ranging from 0 ('Not at all') to 4 ('Extremely'). Higher scores indicate higher potential withdrawal symptoms.
Time frame: Day 1 and Day 14 of each treatment period
Safety Assessment: Change in Clinical Opiate Withdrawal Scale (COWS)
To test the safety of TP by assessing the change in COWS. This validated questionnaire is used to assess common signs and symptoms of opiate withdrawal. Items are scored from 0 to 48. Higher scores indicate higher withdrawal symptoms.
Time frame: Day 1 and Day 14 of each treatment period
Safety Assessments - Electrocardiogram (ECG)
To assess cardiac function based on the change in ECG intervals.
Time frame: Screening, and Day 1, and Day 14 of each treatment period
Safety Assessments - Vitals (Heart Rate)
Change in Heart Rate (beats per minute) from baseline to each study visit.
Time frame: Screening, and from Days 1, 2, 3, 4 and 14 of each treatment period
Safety Assessments - Vitals (Blood Pressure)
Change in Blood Pressure (mmHg) from baseline to each study visit.
Time frame: Screening, and from Days 1, 2, 3, 4 and 14 of each treatment period
Safety Assessments - Vitals (Respiratory Rate)
Change in Respiratory Rate (breaths per minute) from baseline to each study visit.
Time frame: Screening, and from Days 1, 2, 3, 4 and 14 of each treatment period
Safety Assessments - Vitals (Oxygen Saturation)
Change in Oxygen Saturation (SpO2) from baseline to each study visit.
Time frame: Screening, and from Days 1, 2, 3, 4 and 14 of each treatment period
Safety Assessments - Vitals (Body Temperature)
Change in body temperature (°C) from baseline to each study visit.
Time frame: Screening, and from Day 1 to Day 14 of each treatment period
Safety Assessments - Weight (Change from Baseline)
Change from baseline in body weight (kg)
Time frame: Day 1 to Day 14 of each treatment period
Safety Assessments - Body Mass Index (BMI - Change from Baseline)
Change from baseline in body mass index (kg/m²)
Time frame: Day 1 to Day 14 of each treatment period
Safety Assessments - Height
Height (cm) measured at screening only used for calculating body mass index (kg/m²)
Time frame: Screening only
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Hemoglobin)
To assess the safety of TP through the change from baseline to each study visit in hemoglobin (g/L)
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Hematocrit)
To assess the safety of TP through the change from baseline to each study visit in hematocrit (%)
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Red Blood Cell Count)
To assess the safety of TP through the change from baseline to each study visit in red blood cell count (×10E\^12/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Red Cell Distribution Width)
To assess the safety of TP through the change from baseline to each study visit in red cell distribution width.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Mean Corpuscular Volume)
To assess the safety of TP through the change from baseline to each study visit in mean corpuscular volume (fL).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Mean Corpuscular Hemoglobin)
To assess the safety of TP through the change from baseline to each study visit in mean corpuscular hemoglobin (pg).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Mean Corpuscular Hemoglobin Concentration)
To assess the safety of TP through the change from baseline to each study visit in mean corpuscular hemoglobin concentration (g/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - White Blood Cell Count)
To assess the safety of TP through the change from baseline to each study visit in white blood cell count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Neutrophil Count)
To assess the safety of TP through the change from baseline to each study visit in Neutrophil Count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Eosinophil Count)
To assess the safety of TP through the change from baseline to each study visit in Eosinophil Count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Basophil Count)
To assess the safety of TP through the change from baseline to each study visit in Basophil Count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Lymphocyte Count)
To assess the safety of TP through the change from baseline to each study visit in Lymphocyte Count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Monocyte Count)
To assess the safety of TP through the change from baseline to each study visit in Monocyte Count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Platelet Count)
To assess the safety of TP through the change from baseline to each study visit in Platelet Count (×10\^9/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Mean Platelet Volume)
To assess the safety of TP through the change from baseline to each study visit in mean platelet volume (fL)
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Hematology values - Blood Smear Findings)
To assess the safety of TP through the change from baseline to each study visit in blood smear findings.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Blood Urea Nitrogen)
To assess the safety of TP through the change from baseline to each study visit in blood urea nitrogen (mmol/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Creatinine)
To assess the safety of TP through the change from baseline to each study visit in creatinine (umol/L)
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Estimated Glomerular Filtration Rate)
To assess the safety of TP through the change from baseline to each study visit in estimated glomerular filtration rate (ml/min/1.7m\^2).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Albumin)
To assess the safety of TP through the change from baseline to each study visit in albumin (g/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Random Glucose)
To assess the safety of TP through the change from baseline to each study visit in random glucose (mmol/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Fasting Glucose)
To assess the safety of TP through the change from baseline to each study visit in fasting glucose (mmol/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Total Protein)
To assess the safety of TP through the change from baseline to each study visit in total protein (g/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Sodium)
To assess the safety of TP through the change from baseline to each study visit in Sodium (mmol/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Potassium)
To assess the safety of TP through the change from baseline to each study visit in Potassium (mmol/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Clinical Chemistry values - Chloride)
To assess the safety of TP through the change from baseline to each study visit in Chloride (mmol/L).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Aspartate Transaminase)
To assess the safety of TP through the change from baseline to each study visit in Aspartate Transaminase (AST) in U/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Alanine Transaminase)
To assess the safety of TP through the change from baseline to each study visit in Alanine Transaminase (ALT) in mmol/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Gamma-Glutamyl Transferase)
To assess the safety of TP through the change from baseline to each study visit in Gamma-Glutamyl Transferase(GGT) in U/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Total Bilirubin)
To assess the safety of TP through the change from baseline to each study visit in Total Bilirubin in µmol/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Direct Bilirubin)
To assess the safety of TP through the change from baseline to each study visit in Direct Bilirubin in µmol/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Total Bile Acids)
To assess the safety of TP through the change from baseline to each study visit in Total Bile Acids in µmol/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - International Normalized Ratio)
To assess the safety of TP through the change from baseline to each study visit in International Normalized Ratio (INR).
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Glutamate dehydrogenase )
To assess the safety of TP through the change from baseline to each study visit in Glutamate dehydrogenase (GLDH) in U/L.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Coproporphyrin-I)
To assess the safety of TP through the change from baseline to each study visit in Coproporphyrin-I (CP-I) concentration.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Coproporphyrin-III)
To assess the safety of TP through the change from baseline to each study visit in Coproporphyrin-I (CP-III) concentration.
Time frame: Baseline to Day 14 of each treatment period
Safety Assessments - Laboratory Tests (Number of participants with abnormal Liver Function Test values - Alkaline Phosphatase)
To assess the safety of TP through the change from baseline to each study visit in Alkaline Phosphatase (ALP) in U/L.
Time frame: Baseline to Day 14 of each treatment period
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Botanic Tonics, LLC